NCT05846763Recruiting
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
Efficacy and Safety of Obinutuzumab in Combination With Lenalidomide in Patients With Relapsed and Refractory Follicular Lymphoma (R/R FL): A Prospective Observational Study
Source: ClinicalTrials.gov · Last updated 23 May 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is planned to prospectively observe and verify the efficacy and safety of induction therapy with obinutuzumab in combination with lenalidomide followed by maintenance therapy with obinutuzumab and lenalidomide in patients with R/R FL in a real-world setting in a Chinese population.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 27 Apr 2023
- Start date
- 1 Nov 2022
- Primary completion date
- 31 May 2026
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Diseases
- Follicular lymphoma
- NCT number
- NCT05846763
What you commit to
- Study type: Observational
- Planned participants: 50
- From 1 Nov 2022 to the primary completion date, 31 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients currently participating or planning to participate in any interventional clinical trial
- Any other reason that, in the opinion of the investigator, makes the patient unsuitable for this study
Criteria the registry did not label
- Patients must meet the following criteria for study entry::
- Signed Informed Consent Form
- Age ≥ 18 years at enrollment
- At least one prior line of systemic (Stage III-IV) follicular lymphoma therapy
- Relapsed or refractory to front-line anti-lymphoma therapy; refractory is defined as: tumor shrinkage of less than 50% or disease progression after 4 cycles of standard regimen chemotherapy; response to standard regimen chemotherapy, relapse within 24 months; 2 or more relapses, meeting one of the above criteria as refractory lymphoma.
- Conditional treatment with obinutuzumab in combination with lenalidomide
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences Coordinator of this site? Confirm its status | Tianjin | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.